JOHNSON & JOHNSON
JNJ- 交易所
- NYSE
- 產業
- Pharmaceutical Preparations
- SEC CIK
- 0000200406
內部人交易
每一列是一份 Form 4 申報裡同一種交易的合計。預設只顯示公開市場買進（P）與賣出（S）；要看公司授予、行使選擇權等其他代碼，請調整篩選條件。
| 申報時間（美東） | 交易日 | 內部人 | 交易 | 股數 | 均價 | 金額 | 交易後持股 | 持股變化 | 申報 |
|---|---|---|---|---|---|---|---|---|---|
| 2026/9/409:08 ET | 2026/9/2 | Schmid TimothyEVP, WW Chair, MedTech | S賣出Common Stock | −3.36 萬 | $274.74 | −$923.04 萬 | 2.54 萬 | −56.9% | SEC |
| 2026/8/1818:31 ET | 2026/8/17 | Taubert Jennifer LEVP, WWC. Innovative Medicine | S賣出Common Stock | −1.5 萬 | $263.36 | −$395.04 萬 | 19.45 萬 | −7.2% | SEC |
| 2026/8/1416:35 ET | 2026/8/13 | Duato Joaquin執行長、董事長 | S賣出Common Stock | −12.33 萬 | $261.1701 | −$3,219.99 萬 | 27.6 萬 | −30.9% | SEC |
| 2026/8/717:50 ET | 2026/8/5 | Duato Joaquin執行長、董事長 | S賣出Common Stock | −4.85 萬 | $258.1479 | −$1,251.5 萬 | 27.6 萬 | −14.9% | SEC |
| 2026/8/717:44 ET | 2026/8/6 | Forminard Elizabeth執行副總裁、法務長 | S賣出Common Stock | −1.59 萬 | $257.0021 | −$409.1 萬 | 1.7 萬 | −48.4% | SEC |
| 2026/7/2117:27 ET | 2026/7/20 | Broadhurst VanessaEVP, Global Corp Affairs | S賣出Common Stock | −2.31 萬 | $251.266 | −$579.27 萬 | 2.3 萬 | −50.1% | SEC |
| 2026/6/12 | 2026/6/11 | Wengel Kathryn EEVP, Chief TO and Risk Officer | S賣出Common Stock | −1 萬 | $241.15 | −$241.15 萬 | 11.43 萬 | −8.0% | SEC |
| 2026/3/3 | 2026/2/27 | Decker Robert JVP Corporate Controller | S賣出Common Stock | −4,075 | $247.87 | −$101.01 萬 | 2.37 萬 | −14.7% | SEC |
| 2026/2/23 | 2026/2/20 | Schmid TimothyEVP, WW Chair, MedTech | S賣出Common Stock | −1,322 | $245.66 | −$32.48 萬 | 2.54 萬 | −4.9% | SEC |
| 2026/2/18 | 2026/2/13–2/17 | Swanson James D.EVP, CIO | S賣出Common Stock | −6.21 萬 | $243.3917 | −$1,510.98 萬 | 2.57 萬 | −70.7% | SEC |
| 2026/2/18 | 2026/2/17 | Wolk Joseph J執行副總裁、財務長 | S賣出Common Stock | −8.97 萬 | $242.7982 | −$2,176.78 萬 | 1.4 萬 | −86.5% | SEC |
| 2026/2/18 | 2026/2/17 | REED JOHN CEVP, Innovative Medicine, R&D | S賣出Common Stock | −5.39 萬 | $243.00 | −$1,310.52 萬 | 1.07 萬 | −83.5% | SEC |
| 2026/2/18 | 2026/2/18 | Schmid TimothyEVP, WW Chair, MedTech | S賣出Common Stock | −2.26 萬 | $244.3313 | −$552.75 萬 | 2.68 萬 | −45.8% | SEC |
| 2026/2/18 | 2026/2/17 | Broadhurst VanessaEVP, Global Corp Affairs | S賣出Common Stock | −6,197 | $243.39 | −$150.83 萬 | 2.3 萬 | −21.2% | SEC |
| 2026/1/28 | 2026/1/26 | Duato Joaquin執行長、董事長 | S賣出Common Stock | −10 萬 | $221.229 | −$2,212.29 萬 | 3.09 萬 | −76.4% | SEC |
| 2025/12/1 | 2025/11/26 | MORIKIS JOHN G董事 | P買進Common Stock | +1,250 | $206.15 | +$25.77 萬 | 1,848.51 | +208.9% | SEC |
| 2025/10/20 | 2025/10/17 | REED JOHN CEVP, Innovative Medicine, R&D | S賣出Common Stock | −2.17 萬 | $192.71 | −$418.59 萬 | 1.07 萬 | −67.1% | SEC |
| 2025/9/5 | 2025/9/4 | Taubert Jennifer LEVP, WWC. Innovative Medicine | S賣出Common Stock | −5.65 萬 | $177.81 | −$1,004.11 萬 | 17.8 萬 | −24.1% | SEC |
| 2025/8/25 | 2025/8/22 | Duato Joaquin執行長、董事長 | S賣出Common Stock | −12.58 萬 | $179.21 | −$2,254.89 萬 | 27.6 萬 | −31.3% | SEC |
| 2025/8/18 | 2025/8/15 | Wolk Joseph J執行副總裁、財務長 | S賣出Common Stock | −1.68 萬 | $176.91 | −$297.56 萬 | 1.4 萬 | −54.6% | SEC |
| 2025/7/18 | 2025/7/17 | REED JOHN CEVP, Innovative Medicine, R&D | S賣出Common Stock | −1.91 萬 | $163.55 | −$312.99 萬 | 1.07 萬 | −64.2% | SEC |
| 2025/2/26 | 2025/2/25 | Decker Robert JVP Corporate Controller | S賣出Common Stock | −6,999 | $165.88 | −$116.1 萬 | 2.1 萬 | −25.0% | SEC |
| 2025/2/18 | 2025/2/18 | Schmid TimothyEVP, WW Chair, MedTech | S賣出Common Stock | −403 | $156.15 | −$6.29 萬 | 1.51 萬 | −2.6% | SEC |
| 2025/2/11 | 2025/2/7 | Wolk Joseph J執行副總裁、財務長 | S賣出Common Stock | −1.3 萬 | $153.89 | −$200.29 萬 | 0 | −100.0% | SEC |
| 2024/12/12 | 2024/12/12 | WEINBERGER MARK A董事 | P買進Common Stock | +1,000 | $147.22 | +$14.72 萬 | 1,000 | 新建立 | SEC |
| 2024/9/3 | 2024/8/30 | Decker Robert JVP Corporate Controller | S賣出Common Stock | −5,635 | $165.06 | −$93.01 萬 | 1.9 萬 | −22.9% | SEC |
| 2024/3/13 | 2024/3/13 | Broadhurst VanessaEVP, Global Corp Affairs | S賣出Common Stock | −8,891 | $162.16 | −$144.18 萬 | 1.5 萬 | −37.1% | SEC |
| 2024/2/12 | 2024/2/9 | Taubert Jennifer LEVP, WW Chair, Pharmaceuticals | S賣出Common Stock | −5.94 萬 | $156.27 | −$928.2 萬 | 14.14 萬 | −29.6% | SEC |
| 2023/7/27 | 2023/7/25 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −2 萬 | $170.32 | −$340.64 萬 | 10.27 萬 | −16.3% | SEC |
| 2023/7/27 | 2023/7/26 | Hait William見申報附註 | S賣出Common Stock | −1.47 萬 | $172.00 | −$252.81 萬 | 8.77 萬 | −14.3% | SEC |
| 2023/6/14 | 2023/6/12 | Wengel Kathryn EEVP, Chief TO and Risk Officer | S賣出Common Stock | −1.25 萬 | $160.00 | −$199.44 萬 | 6.59 萬 | −15.9% | SEC |
| 2023/3/8 | 2023/3/6 | Swanson James D.見申報附註 | S賣出Common Stock | −1,061.68 | $154.66 | −$16.42 萬 | 9,215.32 | −10.3% | SEC |
| 2022/12/15 | 2022/12/13 | Wolk Joseph J執行副總裁、財務長 | S賣出Common Stock | −1.48 萬 | $179.5999 | −$265.47 萬 | 3.58 萬 | −29.2% | SEC |
| 2022/12/2 | 2022/11/30 | McEvoy AshleyEVP, WW Chair, MedTech | S賣出Common Stock | −7.33 萬 | $175.472 | −$1,286.61 萬 | 4.18 萬 | −63.7% | SEC |
| 2022/11/23 | 2022/11/22 | Taubert Jennifer LEVP, WW Chair, Pharmaceuticals | S賣出Common Stock | −7.69 萬 | $176.78 | −$1,359.84 萬 | 12.65 萬 | −37.8% | SEC |
| 2022/11/21 | 2022/11/18 | Decker Robert J主計長、會計主管 | S賣出Common Stock | −1.69 萬 | $175.00 | −$296.24 萬 | 1.55 萬 | −52.2% | SEC |
| 2022/11/10 | 2022/11/9 | Wengel Kathryn EEVP, Chief GSC Officer | S賣出Common Stock | −1.64 萬 | $173.42 | −$284.58 萬 | 7.13 萬 | −18.7% | SEC |
| 2022/11/8 | 2022/11/4 | Mongon ThibautExec VP, WW Chair, Consumer | S賣出Common Stock | −3.52 萬 | $171.1815 | −$603.35 萬 | 4.01 萬 | −46.8% | SEC |
| 2022/10/26 | 2022/10/24 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −2.93 萬 | $171.36 | −$501.66 萬 | 11.47 萬 | −20.3% | SEC |
| 2022/10/26 | 2022/10/24 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −2.09 萬 | $171.1916 | −$356.95 萬 | 14.4 萬 | −12.7% | SEC |
| 2022/10/26 | 2022/10/24 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −1.3 萬 | $171.2208 | −$222.55 萬 | 16.48 萬 | −7.3% | SEC |
| 2022/10/26 | 2022/10/24 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −8,256 | $171.139 | −$141.29 萬 | 17.99 萬 | −4.4% | SEC |
| 2022/10/26 | 2022/10/24 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −4,263 | $171.1263 | −$72.95 萬 | 18.49 萬 | −2.3% | SEC |
| 2022/10/26 | 2022/10/24 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −2,815 | $171.0209 | −$48.14 萬 | 18.98 萬 | −1.5% | SEC |
| 2022/10/26 | 2022/10/24 | Hait William見申報附註 | S賣出Common Stock | −1.5 萬 | $171.55 | −$257.33 萬 | 8.02 萬 | −15.8% | SEC |
| 2022/10/21 | 2022/10/19 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −2.29 萬 | $164.50 | −$376.11 萬 | 11.47 萬 | −16.6% | SEC |
| 2022/10/21 | 2022/10/19 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −2.99 萬 | $164.50 | −$492.61 萬 | 13.62 萬 | −18.0% | SEC |
| 2022/10/21 | 2022/10/19 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −1.37 萬 | $164.50 | −$225.41 萬 | 16.75 萬 | −7.6% | SEC |
| 2022/10/21 | 2022/10/19 | Fasolo Peter執行副總裁、人資長 | S賣出Common Stock | −3,613 | $164.50 | −$59.43 萬 | 18.12 萬 | −2.0% | SEC |
| 2022/6/14 | 2022/6/10 | Wengel Kathryn EEVP, Chief GSC Officer | S賣出Common Stock | −4 萬 | $173.00 | −$692 萬 | 7.13 萬 | −35.9% | SEC |